NIAID Sponsors Phase I Clinical Trial of mAb CIS43LS Targeting Malaria

NIAID Sponsors Phase I Clinical Trial of mAb CIS43LS Targeting Malaria

The National Institute of Allergy and Infectious Diseases (NIAID) has developed a monoclonal antibody (mAb) called mAb CIS43LS targeting malaria. They are now enrolling healthy adult volunteers in a Phase I clinical trial testing the safety and effectiveness of the...
Monash Receives Another $76 Million for Medical Research Breaking the Record

Monash Receives Another $76 Million for Medical Research Breaking the Record

Australia’s National Health and Medical Research Council (NHMRC) awards Monash University over $75 million. This award is the largest among a total of over $400 million allocated to various research centers reports Federal Health Minister Greg Hunt. Medical research...
Gold Coast Investigators Quest for Malaria Vaccine

Gold Coast Investigators Quest for Malaria Vaccine

Australia’s Gold Coast truly represents one of the most beautiful places in the world. Its Griffith University Institute for Glycomics received $500,000 from the government earlier this year to support their ongoing clinical trials program aiming to test the...

Pin It on Pinterest